Valeant Pharmaceuticals International Inc. (VRX) Trading Up 7.8%
Valeant Pharmaceuticals International Inc. (NYSE:VRX) shares were up 7.8% during mid-day trading on Monday . The stock traded as high as $31.25 and last traded at $30.97, with a volume of 38,084,142 shares traded. The stock had previously closed at $28.74.
Several research analysts have recently issued reports on VRX shares. Rodman & Renshaw reaffirmed a “buy” rating and set a $105.00 price target on shares of Valeant Pharmaceuticals International in a research note on Tuesday, April 26th. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Valeant Pharmaceuticals International in a research note on Tuesday, April 26th. Canaccord Genuity reaffirmed a “hold” rating and set a $40.00 price target on shares of Valeant Pharmaceuticals International in a research note on Wednesday, April 27th. Mizuho reaffirmed an “underperform” rating and set a $18.00 price target on shares of Valeant Pharmaceuticals International in a research note on Thursday, April 28th. Finally, BMO Capital Markets reaffirmed a “positive” rating on shares of Valeant Pharmaceuticals International in a research note on Friday, April 29th. Six investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Valeant Pharmaceuticals International currently has a consensus rating of “Hold” and a consensus target price of $60.32.
The company has a 50-day moving average price of $24.36 and a 200 day moving average price of $36.22. The company’s market capitalization is $10.84 billion.
Valeant Pharmaceuticals International (NYSE:VRX) last released its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.48 by $0.08. The company earned $2.42 billion during the quarter, compared to analyst estimates of $2.47 billion. The business’s revenue was down 11.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.14 earnings per share. Analysts anticipate that Valeant Pharmaceuticals International Inc. will post $6.54 earnings per share for the current year.
In other Valeant Pharmaceuticals International news, CEO Joseph C. Papa purchased 202,000 shares of the stock in a transaction on Friday, June 10th. The shares were purchased at an average price of $24.48 per share, with a total value of $4,944,960.00. Following the completion of the transaction, the chief executive officer now directly owns 2,442,199 shares in the company, valued at $59,785,031.52. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Argeris N. Karabelas purchased 4,000 shares of the stock in a transaction on Thursday, August 11th. The shares were acquired at an average cost of $24.65 per share, for a total transaction of $98,600.00. Following the transaction, the director now owns 20,726 shares of the company’s stock, valued at $510,895.90. The disclosure for this purchase can be found here.
An institutional investor recently bought a new position in Valeant Pharmaceuticals International stock. State of New Jersey Common Pension Fund D purchased a new position in Valeant Pharmaceuticals International Inc. (NYSE:VRX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 20,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,033,000.
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.